Bayer targets €3bn+ peak with soy traits and 2029 margin
Bayer is launching commercial soy traits targeting >€3bn peak sales and expanding R&D, digital tools and biologicals to reach above-market growth and ~25% EBITDA margin by 2029, while managing Climara supply shortfall to early 2027.
Bayer AG is pushing growth by launching commercial soy traits targeting more than €3bn in peak sales and by expanding R&D, digital tools and biologicals to reach above-market growth and about a 25% EBITDA margin by 2029. S. drug-pricing pact.